Sirolimus only exhibited anti-GBM effects in PTEN-deficient GBM patients as a single therapeutic agent, and has demonstrated limited additional benefit when combined with EGFR inhibitor, erlotinib [111, 112]. Here, PTEN is linked to glioblastoma.